Compare Hasbro, Inc. (HAS) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hasbro, Inc. vs Eli Lilly And Co — how do they compare? Hasbro, Inc. trades at $92.69 (market cap $12.80B), while Eli Lilly And Co trades at $1,166.65 (market cap $1.06T). The key difference: Eli Lilly And Co is far larger — about 82.8× Hasbro, Inc.'s market cap, and Hasbro, Inc. pays the higher dividend (3.09%). Which is the better fit depends on your goals — on Pluang, investors hold Hasbro, Inc. for 97 Days and Eli Lilly And Co for 93 Days on average.
| HAS | LLY | |
|---|---|---|
Market Cap | $12.80B | $1.06T |
Volume | 1,356,688 | 2,297,239 |
Sector | Consumer Cyclical | Health |
52-Week High | $105.88 | $1.28K |
52-Week Low | $70.95 | $799.57 |
Typical Hold Time | 97 Days | 93 Days |
Enterprise Value | $14.99B | $1.11T |
Dividend Yield | 3.09% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) trades at $92.50, up 1.61% today, with a bullish technical outlook and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 20, 2026. Revenue is projected to grow to $5.0B in 2026, with net income rebounding to $794M. The company maintains a solid gross profit margin of 64.41% and positive operating cash flow, though it carries significant long-term debt of $3.38B.
The outlook is positive, driven by earnings momentum and cost-saving initiatives, but risks include high debt levels and competitive pressures. Analyst price targets suggest upside potential, with a consensus target of $107.60. Investors should monitor the upcoming earnings report for confirmation of growth trends and debt management progress.
Eli Lilly (LLY) trades at $1,169.93, up 1.07% on the day, with a bullish technical signal and strong fundamental momentum. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $8.38 exceeding the $6.40 estimate. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Positive news flow highlights promising pipeline updates in weight-loss and diabetes drugs, reinforcing growth prospects.
Outlook remains favorable given dominant market position and innovation pipeline, though high valuation multiples pose a risk. Analyst consensus is strongly bullish with a $1,340 price target. Key risks include competitive pressures and execution challenges in scaling production to meet demand for blockbuster therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
